RAMADAN
Saturday, July 16, 2022
New Psychiatric Disorders Appeared in Healthy Individuals Following Vaccination
Monday, June 20, 2022
دراسة تتوصل إلى أن لقاح كوفيد-19 من فايزر ينتقل إلى خلايا الكبد ويتحول إلى حمض نووي دي إن إيه- كل يوم يكتشف أن اللقاحات لا فائدة منها ومع هذا مصرين على إعطائها للناس ونحن كالعادة تابعين
Pfizer’s COVID-19 Vaccine
Goes Into Liver Cells and Is Converted to DNA: Study
BY MEILING LEE TIMEMARCH 1, 2022 PRINT
The messenger RNA
(mRNA) from Pfizer’s COVID-19 vaccine
is able to enter human liver cells and is converted into DNA,
according to Swedish researchers at Lund University.
The researchers
found that when the mRNA vaccine enters the human liver cells, it triggers the
cell’s DNA, which is inside the nucleus, to increase the production of the
LINE-1 gene expression to make mRNA.
The mRNA then
leaves the nucleus and enters the cell’s cytoplasm, where it translates into
LINE-1 protein. A segment of the protein called the open reading frame-1, or
ORF-1, then goes back into the nucleus, where it attaches to the vaccine’s mRNA
and reverse transcribes into spike DNA.
Reverse
transcription is when DNA is made from RNA, whereas the normal transcription
process involves a portion of the DNA serving as a template to make an mRNA
molecule inside the nucleus.
“In this study we
present evidence that COVID-19 mRNA vaccine BNT162b2 is able to enter the human
liver cell line Huh7 in vitro,” the researchers wrote in the study, published
in Current Issues of Molecular Biology. “BNT162b2 mRNA is reverse
transcribed intracellularly into DNA as fast as 6 [hours] after BNT162b2
exposure.”
BNT162b2 is
another name for the Pfizer-BioNTech COVID-19 vaccine that is marketed under
the brand name Comirnaty.
The whole process
occurred rapidly within six hours. The vaccine’s mRNA converting into DNA and
being found inside the cell’s nucleus is something that the Centers for Disease
Control and Prevention (CDC) said would not happen.
“The genetic
material delivered by mRNA vaccines never enters the nucleus of your cells,”
the CDC said on its web page titled “Myths and Facts about COVID-19 Vaccines.”
This is the first
time that researchers have shown in vitro or inside a petri dish how an mRNA
vaccine is converted into DNA on a human liver cell line, and is what health
experts and fact-checkers said for over a year couldn’t occur.
The CDC says that
the “COVID-19 vaccines do not change or interact with your DNA in any way,”
claiming that all of the ingredients in both mRNA and viral vector COVID-19
vaccines (administered in the United States) are discarded from the body once
antibodies are produced. These vaccines deliver genetic material that instructs
cells to begin making spike proteins found on the surface of SARS-CoV-2 that
causes COVID-19 to produce an immune response.
Pfizer didn’t
comment on the findings of the Swedish study and said only that its mRNA
vaccine does not alter the human genome.
“Our COVID-19
vaccine does not alter the DNA sequence of a human cell,” a Pfizer spokesperson
told The Epoch Times in an email. “It only presents the body with the
instructions to build immunity.”
More than 215
million or 64.9 percent of Americans are fully vaccinated as of Feb. 28, with
94 million having received a booster dose.
Autoimmune Disorders
The Swedish study
also found spike proteins expressed on the surface of the liver cells that
researchers say may be targeted by the immune system and possibly cause
autoimmune hepatitis, as “there [have] been case reports on individuals who
developed autoimmune hepatitis after BNT162b2 vaccination.”
The authors of
the first reported case of a healthy 35-year-old female who
developed autoimmune hepatitis a week after her first dose of the Pfizer
COVID-19 vaccine said that there is a possibility that “spike-directed
antibodies induced by vaccination may also trigger autoimmune conditions in
predisposed individuals” as it has been shown that “severe cases of SARS-CoV-2
infection are characterized by an autoinflammatory dysregulation that
contributes to tissue damage,” which the virus’s spike protein appears to be
responsible for.
Spike proteins
may circulate in the body after an infection or injection with a COVID-19
vaccine. It was assumed that the vaccine’s spike protein would remain mostly at
the injection site and last up to several weeks like other proteins produced in
the body. But studies are showing that is not the case.
The Japanese
regulatory agency’s biodistribution study of the Pfizer vaccine showed that some of the mRNAs moved
from the injection site and through the bloodstream, and were found in various
organs such as the liver, spleen, adrenal glands, and ovaries of rats 48 hours
following injection.
In a different study,
the spike proteins made in the body after receiving a Pfizer COVID-19 shot have
been found on tiny membrane vesicles called exosomes—that mediate cell-to-cell
communication by transferring genetic materials to other cells—for at least
four months after the second vaccine dose.
The persistence
of the spike protein in the body “raises the prospect of sustained inflammation
within and damage to organs which express the spike protein,” according to
experts at Doctors for COVID Ethics, an organization consisting of
physicians and scientists “seeking to uphold medical ethics, patient safety,
and human rights in response to COVID-19.”
“As long as the
spike protein can be detected on cell-derived membrane vesicles, the immune
system will be attacking the cells that release these vesicles,” they said.
Dr. Peter
McCullough, an internist, cardiologist, and epidemiologist, wrote on Twitter that the Swedish study’s findings have
“enormous implications of permanent chromosomal change and long-term
constitutive spike synthesis driving the pathogenesis of a whole new genre of
chronic disease.”
Whether the
findings of the study will occur in living organisms or if the DNA converted
from the vaccine’s mRNA will integrate with the cell’s genome is unknown. The
authors said more investigations are needed, including in whole living
organisms such as animals, to better understand the potential effects of the
mRNA vaccine.
“At this stage,
we do not know if DNA reverse transcribed from BNT162b2 is integrated into the
cell genome. Further studies are needed to demonstrate the effect of BNT162b2
on genomic integrity, including whole genome sequencing of cells exposed to
BNT162b2, as well as tissues from human subjects who received BNT162b2
vaccination,” the authors said.
Thursday, May 19, 2022
الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة!!!!
Pfizer’s COVID Vaccine Protection Against Omicron Fades After a Few Weeks: Study
الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة
The protection afforded against the Omicron coronavirus variant fades quickly after a second and third dose of Pfizer–BioNtech’s COVID-19 vaccine, according to a peer-reviewed study published in the JAMA Network.
الحماية الممنوحة ضد متغير فيروس
كورونا أوميكرون تتلاشى بسرعة بعد الجرعة الثانية والثالثة من لقاح COVID-19 من شركة فايزر Pfizer –
BioNtech ، وفقًا لدراسة تمت
مراجعتها من قِبل النشرات العلمية ونشرت في شبكة JAMA.
A Danish study published in the JAMA Network on May 13 found that there was a rapid decline in Omicron-specific serum neutralizing antibodies only a few weeks after the administration of the second and third doses of the vaccine.
وجدت دراسة دنماركية نُشرت في شبكة JAMA في 13 مايو أن هناك
انخفاضًا سريعًا في الأجسام المضادة المعادلة لمصل أوميكرون بعد أسابيع قليلة فقط
من إعطاء الجرعتين الثانية والثالثة من اللقاح.
The study evaluated 128 adults who were vaccinated, and of that number, 73 people received two doses of the Pfizer vaccine, and 55 people received three doses between January 2021 and October 2021 or were previously infected before February 2021, and then vaccinated.
قامت الدراسة بتقييم 128 بالغًا تم تطعيمهم ، ومن هذا العدد تلقى 73 شخصًا جرعتين من لقاح فايزر ، وتلقى 55 شخصًا ثلاث جرعات بين يناير 2021 وأكتوبر 2021 أو أصيبوا سابقًا قبل فبراير 2021 ، ثم تم تطعيمهم.
“Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses,” an abstract of the study reads. “The observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction–confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom.”
ملخص الدراسة: "وجدت دراستنا
انخفاضًا سريعًا في عيار الأجسام المضادة الخاصة بأوميكرون المصل المحدد بعد
أسابيع قليلة فقط من الجرعتين الثانية والثالثة". "الانخفاض الملحوظ في
عيار الأجسام المضادة المعادلة للسكان يتوافق مع انخفاض فعالية اللقاح ضد تفاعل
البلمرة المتسلسل - عدوى Omicron المؤكدة في الدنمارك وعدوى Omicron المصحوبة بأعراض في
المملكة المتحدة."
The antibody levels, which are associated with protection against future infections, dropped within a few weeks of getting the vaccine doses. They were also much lower than the antibodies specific to the Delta and original COVID-19 strains, according to the study.
انخفضت مستويات الأجسام المضادة ، المرتبطة
بالحماية من العدوى المستقبلية ، في غضون أسابيع قليلة من الحصول على جرعات
اللقاح. كانت أيضًا أقل بكثير من الأجسام المضادة الخاصة بدلتا وسلالات COVID-19 الأصلية ، وفقًا للدراسة.
The proportion of Omicron-specific antibodies fell to 53 percent between the eighth and tenth week from 76 percent four weeks after the second dose. At weeks 12 to 14, these levels dropped even more to only 19 percent, according to the study.
انخفضت نسبة الأجسام المضادة الخاصة بأوميكرون
إلى 53 بالمائة بين الأسبوعين الثامن والعاشر من 76 بالمائة بعد أربعة أسابيع من
الجرعة الثانية. في الأسابيع من 12 إلى 14 ، انخفضت هذه المستويات أكثر إلى 19 في
المائة فقط ، وفقًا للدراسة.
Those antibodies increased with a third dose, increasing 21-fold three weeks after the dose before dropping to eightfold at week four. But with the third dose, antibody levels dropped as early as three weeks, falling 5.4-fold between the third and eighth week, the researchers said.
زادت هذه الأجسام المضادة بجرعة ثالثة ، وزادت بمقدار 21 ضعفًا بعد ثلاثة أسابيع من الجرعة قبل أن تنخفض إلى ثمانية أضعاف في الأسبوع الرابع. لكن مع الجرعة الثالثة ، انخفضت مستويات الأجسام المضادة في وقت مبكر يصل إلى ثلاثة أسابيع ، وانخفضت بمقدار 5.4 أضعاف بين الأسبوعين الثالث والثامن ، كما قال الباحثون.
They concluded that it may be needed to provide additional booster doses to combat the Omicron variant, which emerged last fall, primarily among older individuals.
وخلصوا إلى أنه قد تكون هناك حاجة لتوفير جرعات معززة إضافية لمكافحة متغير أوميكرون الذي ظهر في الخريف الماضي ، بشكل أساسي بين الأفراد الأكبر سنًا.
However, a study from Israeli researchers published in early April in the New England Journal of Medicine found that a fourth dose, or a second booster, of the Pfizer vaccine, doesn’t offer strong protection.
“Overall, these analyses provided evidence for the effectiveness of a fourth vaccine dose against severe illness caused by the omicron variant, as compared with a third dose administered more than 4 months earlier,” the study’s authors wrote at the time, after analyzing data from the Israeli Ministry of Health. “For confirmed infection, a fourth dose appeared to provide only short-term protection and a modest absolute benefit.”
Friday, May 6, 2022
هيئة الغذاء والدواء الأمريكية تقيد إستخدام لقاح جونسون لأنه يسبب تجلطات دموية
Johnson & Johnson Covid-19 Vaccine Use Limited By US Food And Drug Administration Advisory
The FDA said in a statement that the change is because of a risk of a clotting condition called thrombosis with thrombocytopenia syndrome (TTS) from use of the vaccine.
Thursday’s announcement is sure to fuel further concerns among those who have resisted Covid-19 vaccinations. Many people have cited concerns about vaccinations that were rushed to market without the usual years-long vetting on potential long-term effects. While those fears have been derided as “conspiracy theories,” today’s ruling will give pause on whether the resistance was grounded in logic.
“We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. … Today’s action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our actions.”
The new marching orders applies to first shots and any boosters.
Despite the warning, the FDA said the J&J vaccine’s blood clotting problem is still better than not being vaccinated. It gave several examples of those who may still benefit, including: :
Those who had a severe allergic reaction to an mRNA vaccine, such as those from Pfizer/BioNTech or Moderna;
Those with personal concerns about the mRNA vaccines who would remain unvaccinated without the J&J vaccine;
Those with limited access to mRNA Covid-19 vaccines.
Moe than 18.7 million doses of the J&J vaccine have been administered in the US, according to the US Centers for Disease Control and Prevention. It estimated that 7.7% of those who received the J&J vaccine are considered fully vaccinated.
In an updated fact sheet on the vaccine, the FDA says that 15% of TTS cases have been fatal.
The agency’s updated analysis of the vaccine includes cases reported to its Vaccine Adverse Events Reporting System (VAERS) database through March 18. The FDA says it has confirmed 60 cases of TTS, including nine deaths.
Wednesday, December 8, 2021
عجيب أمر شركات اللقاحات! اللقاح فعال لمتحور أوميكرون ، بعدها بكام سطر مش أكيد فاعليته بعدها بكام سطر ممكن عمل لقاح جديد خاص للمتحور في خلال 6 أسابيع! أيهم الصحيح
Pfizer says booster dose of vaccine protects against omicron variant
A booster dose of the Pfizer-BioNTech Covid-19 vaccine appears to provide strong protection against the omicron variant, the companies announced Wednesday.
أعلنت شركة فايزر يوم الأربعاء أن الجرعة المعززة من لقاحها بايو إن تيك كوفيد-19 يوفر حماية قوية لمتحور أوميكرون
They said a third dose of their vaccine provides a similar level of neutralizing antibodies to omicron, comparable to two doses against the original coronavirus and other variants that have emerged.
Blood samples from those who received only the primary series of the vaccine, on average, did see a 25-fold drop in antibodies against the new variant, indicating that two doses of the vaccine may not be sufficient to protect against infection with omicron.
The companies said the results are preliminary. The findings were detailed in a press release, and the full data have not yet been made available for other scientists to scrutinize.
But lab studies are only one piece of the puzzle. Other data are also needed to determine whether a new vaccine is needed. Scientists need to understand transmissible the omicron variant is (early indications suggest it's more contagious than the delta variant) as well as how sick it makes people (early data suggests the illness caused by the variant is milder).
The results from Pfizer-BioNTech are the first announced by vaccine makers. Tuesday, a South Africa research institute also released lab results on how the Pfizer vaccine fared against omicron, showing about a fortyfold reduction in vaccine-induced antibodies that could neutralize the new variant. That study didn't look at booster shots, however.
Pfizer-BioNTech has previously said it could develop a variant-specific vaccine within six weeks and ship initial batches within 100 days.
Moderna and Johnson & Johnson are expected to release lab results from the omicron variant in the coming days. Academic research institutions are also looking into how well the vaccine works against omicron.
Monday, December 6, 2021
https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html
What We Know about Omicron
Infection and Spread
- How easily does Omicron spread? The Omicron variant likely will spread more easily than the original SARS-CoV-2 virus and how easily Omicron spreads compared to Delta remains unknown. CDC expects that anyone with Omicron infection can spread the virus to others, even if they are vaccinated or don’t have symptoms.
- من المحتمل أن ينتشر متحور اوميكرون بسهولة أكبر من فيروس كوفيد-19 الأصلي وبالنسبة لمدى سهولة أنتشار أوميكرون مقارنة ب متحور دلتا، لازال غير معروف للعلماء، ويتوقع مركز التحكم والسيطرة على الأمراض أن آي شخص مصاب بعدوى اوميكرون يمكن أن ينشر الفيروس للأخرين حتى لمن حصل على التطعيمين أو من لا يظهر عليه أعراض
- Will Omicron cause more severe illness? More data are needed to know if Omicron infections, and especially reinfections and breakthrough infections in people who are fully vaccinated, cause more severe illness or death than infection with other variants.
- هناك حاجة للمزيدمن المعلومات والبيانات لمعرفة ما إذا كانت عدوى أميكرون العدوى والإصابات في الأشخاص الذين تم تطعيمهم تسبب مرضاً شديداً أو وفاة بطريقة أكبر من المتحورات السابقة
- Will vaccines work against Omicron? Current vaccines are expected to protect against severe illness, hospitalizations, and deaths due to infection with the Omicron variant. However, breakthrough infections in people who are fully vaccinated are likely to occur. With other variants, like Delta, vaccines have remained effective at preventing severe illness, hospitalizations, and death. The recent emergence of Omicron further emphasizes the importance of vaccination and boosters.
- Will treatments work against Omicron? Scientists are working to determine how well existing treatments for COVID-19 work. Based on the changed genetic make-up of Omicron, some treatments are likely to remain effective while others may be less effective.
- هل ستكون العلاجات واللقاحات الحالية فعالة مع متحور أميكرون؟
- مازال العلماء يعملون على تحديد مدى نجاح العلاجات الحالية ل كوفيد-19 بناءً على التركيب الجيني المتغير لاوميكرون ، ومن المرجح أن تظل بعض تلك العلاجات فعالة بينما قد يكون البعض الآخر أقل فاعلية. ومن عندي أول لا فاعليه لها على الإطلاق
We have the Tools to Fight Omicron
Vaccines remain the best public health measure to protect people from COVID-19, slow transmission, and reduce the likelihood of new variants emerging. COVID-19 vaccines are highly effective at preventing severe illness, hospitalizations, and death. Scientists are currently investigating Omicron, including how protected fully vaccinated people will be against infection, hospitalization, and death. CDC recommends that everyone 5 years and older protect themselves from COVID-19 by getting fully vaccinated. CDC recommends that everyone ages 18 years and older should get a booster shot at least two months after their initial J&J/Janssen vaccine or six months after completing their primary COVID-19 vaccination series of Pfizer-BioNTech or Moderna.
Masks offer protection against all variants. CDC continues to recommend wearing a mask in public indoor settings in areas of substantial or high community transmission, regardless of vaccination status. CDC provides advice about masks for people who want to learn more about what type of mask is right for them depending on their circumstances.
Tests can tell you if you are currently infected with COVID-19. Two types of tests are used to test for current infection: nucleic acid amplification tests (NAATs) and antigen tests. NAAT and antigen tests can only tell you if you have a current infection. Individuals can use the COVID-19 Viral Testing Tool to help determine what kind of test to seek. Additional tests would be needed to determine if your infection was caused by Omicron. Visit your state, tribal, local, or territorial health department’s website to look for the latest local information on testing.
Self-tests can be used at home or anywhere, are easy to use, and produce rapid results. If your self-test has a positive result, stay home or isolate for 10 days, wear a mask if you have contact with others, and call your healthcare provider. If you have any questions about your self-test result, call your healthcare provider or public health department.
Until we know more about the risk of Omicron, it is important to use all tools available to protect yourself and others.
What CDC is Doing to Learn about Omicron
Virus Characteristics
CDC scientists are working with partners to gather data and virus samples that can be studied to answer important questions about the Omicron variant. Scientific experiments have already started. CDC will provide updates as soon as possible.
Variant Surveillance
In the United States, CDC uses genomic surveillance to track variants of SARS-CoV-2, the virus that causes COVID-19 to more quickly identify and act upon these findings to best protect the public’s health. CDC established multiple ways to connect and share genomic sequence data being produced by CDC, public health laboratories, and commercial diagnostic laboratories within publicly accessible databases maintained by the National Center for Biotechnology Informationexternal icon (NCBI) and the Global Initiative on Sharing Avian Influenza Dataexternal icon (GISAID). CDC’s national genomic surveillance can detect a variant that is circulating at 0.1% frequency with 99% statistical confidence.
Friday, October 8, 2021
Pfizer's COVID-19 immunity protection diminishes after 2 months المناعة تتضائل إلى 20% بعد 4 شهور حتى بعد جرعتين من لقاح فايزر
Pfizer's COVID-19 immunity protection diminishes after 2 months, and it can reach as low as 20% after 4 months: studies
Two recent studies found that Pfizer's immunity protection diminishes rapidly a few months after a person has their second dose.
بعد القيام بدراستين حديثتين وجد أن الحماية المناعية للقاح فايزر تتضائل سريعاً في أشهر قليلة للأفراد الذين حصلوا على الجرعة الثانية
However, one study noted that the vaccine's protection against death and hospitalization still remained as high as 96%.
بالرغم من ذلك فإن أحد الدراستين أشارت أن حماية اللقاح ضد الوفاة أو دخول المشفى مازالت مرتفة إلى 96% تقريبا
The studies affirm Pfizer's earlier comments that its vaccines may not defend against COVID-19 infection as effectively over time.
الدراسات أكدت تعقيبات فايزر السابقة أن لقاحهم ربما لا يحمي من عدوى كوفيد-19 بفاعلية مع مرور الوقت
COVID-19 immunity protection from two doses of the Pfizer vaccine starts dwindling after about two month, still, the shots remain effective in guarding against hospitalization and death, according to a pair of studies published in the New England Journal of Medicine on Wednesday.
The new findings affirm what Pfizer, Moderna, and the Centers for Disease Control and Prevention have indicated in recent weeks - that the vaccines' ability to protect the body from coronavirus infection may wane over time. Last month, the Food and Drug Administration authorized Pfizer booster shots for older or more vulnerable people.
In the first study, researchers from Qatar found that Pfizer's immunity protection drops to as low as 20% just four months after a person receives their second dose. They based their report on observations of infections among Qatar's over 900,000 vaccinated people.
The researchers found that Pfizer's protection against infection was "negligible" shortly after the first dose, but jumps to 36.8% three weeks later. When people receive their second dose, immunity protection increases to 77.5% after about a month.
But once that month is over, Pfizer's immunity effectiveness declines steadily, hovering at around 20% after the four-month mark, per the researchers.
"These findings suggest that a large proportion of the vaccinated population could lose its protection against infection in the coming months, perhaps increasing the potential for new epidemic waves," wrote the report.
Still, Pfizer's protection against hospitalization and death remained "robust" at 90% or higher for six months after the second dose, it said. The report also noted that its findings may not apply well to countries with older populations, since Qatar's population is relatively young with only 9% of its people being 50 or older.
The other study, conducted in Israel, looked at 4,868 healthcare workers. It reported that people have substantially decreased COVID-19 antibodies just six months after receiving their second dose of Pfizer's vaccine.
The drop is especially prominent among men, the elderly above 65, and those with weakened immune systems.
In comparison, vaccines for other conditions such as mumps, measles, and rubella only show small decreases of about 5% to 10% each year in neutralizing antibody levels, wrote the researchers.
They also noted that they observed higher antibody counts in obese participants who have a body mass index of 30 or above.
"Yet, it is still unclear whether vaccinated obese persons are at higher or lower risk for breakthrough infection and whether the relatively high humoral response to the vaccine is protective," the report stated.
خلاصة ما سبق وكل ما يدور منذ عامين أن اللقاح ليس فعالاً طول العمر ولا حتى لسنوات بل وجد أنه حتى من تعاطى الجرعة المحفزة كما يسمونها أو المنشطة أيضاً تتلاشى فاعليتها بعد فترة آي أن كل من أخذ الجرعتين بعد 6 أشهر من الجرعة الثانية وقد يكون بعد 120 يوم فقط تقل المناعة لديه وسيستمر هذا الأمر والسؤال هل سيصبح مثل لقاح الأنفلونزا (الرباعي الآن) أم ماذا؟ كذلك بدأت تجارب كبسولات تعطى لمن أصيب بالمرض في الأيام الأولى (لا يزيد عن 5 أيام) وهي تمنع أنتشار وتكاثر المرض لديه عن طريق تبديل معين يؤدي إلى إعطاء إشارات خاطئة للفايرس عند تكوين مزيد منه فلا يتكاثر ومازال الأمر تحت البحث (ملحوظة أخيرة كل ما أكتبه هنا هو من مواقع طبية ونشرات ومجلات يتم نشرها أو مرئيات ومناقشات أستمع إليها) يعني من الآخر أنا لست طبيباً ولكني أحب القراءة
Thursday, September 23, 2021
مع أقتراب موعد مصل (لقاح الأنفلونزا) قد تم تعديل وترقية اللقاح ليصبح رباعي وهذه معلومات أولية عن اللقاح ولكن للأسف لأمريكا ولكن المعلومات تفيد الجميع
Quadrivalent Influenza Vaccine
Brand names: AFLURIA Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, Flucelvax Quadrivalent and Fluzone Quadrivalent, FluMist Quadrivalent
What is quadrivalent flu vaccine?
A quadrivalent influenza (flu) vaccine is designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses.
Why was quadrivalent flu vaccine developed?
For many years, flu vaccines were designed to protect against three different flu viruses: an influenza A(H1N1) virus, an influenza A(H3N2) virus and one influenza B virus, even though there are two different lineages of B viruses that circulate during most seasons. Adding a B virus from the second lineage was done to give broader protection against circulating flu viruses.
Who can get quadrivalent flu vaccine?
من يمكن أن يأخذ لقاح الأنفلونزا رباعي التكافؤ؟
All flu vaccines in the United States for the 2021-2022 season are quadrivalent vaccines. Different vaccines are approved for different age groups. There is a quadrivalent flu shot that can be given to children as young as 6 months old. Flucelvax Quadrivalent is now approved for people 2 years and older. More information on approved flu vaccines for the 2020-2021 flu season, and age indications for each vaccine are available in CDC’s
الأشخاص العاديين من سن عامين إلى 49 سنة والمرأة غير الحامل يمكن أن تأخذ المصل بخاخ الأنف ولكن الأشخاص الذين يعانون من حالات مرضية معينة يجب أن لا يتعاطو اللقاح بخاخ الأنف
The quadrivalent nasal spray vaccine is approved for use in non-pregnant individuals, 2 years through 49 years old. People with certain medical conditions should not receive the nasal spray influenza vaccine.
Who shouldn’t get quadrivalent flu vaccine?
من الذي يجب أن لا يأخذ لقاح الأنفلونزا ؟
Different influenza (flu) vaccines are approved for use in people in different age groups. In addition, some vaccines are not recommended for certain groups of people. Factors that can determine a person’s suitability for vaccination, or vaccination with a particular vaccine, include a person’s age, health (current and past) and any allergies to flu vaccine or its components.
People who SHOULD NOT get a flu shot include:
Children younger than 6 months of age are too young to get a flu shot.
People with severe, life-threatening allergies to any ingredient in a flu vaccine (other than egg proteins) should not get that vaccine. This might include gelatin, antibiotics, or other ingredients.
People who have had a severe allergic reaction to a dose of influenza vaccine should not get that flu vaccine again and might not be able to receive other influenza vaccines. If you have had a severe allergic reaction to an influenza vaccine in the past, it is important to talk with your health care provider to help determine whether vaccination is appropriate for you.
Are any of the available flu vaccines recommended over the others?
هل يوجد لقاح يوصى به خير من أخر؟ بالطبع لا ولكن يوجد لقاح لا يصلح لأشخاص معينين بسبب حالات حساسية أو أمراض لديهم فيأخذ بديل مثل من لديهم حساسية من البيض
For the 2021-2022 flu season, the Advisory Committee on Immunization Practices (ACIP) recommends annual influenza (flu) vaccination for everyone 6 months and older with any licensed, influenza vaccine that is appropriate for the recipient’s age and health status, including inactivated influenza vaccine (IIV4), recombinant influenza vaccine (RIV4), or live attenuated nasal spray influenza vaccine (LAIV4) with no preference expressed for any one vaccine over another.
There are many vaccine options to choose from, but the most important thing is for all people 6 months and older to get a flu vaccine every year. If you have questions about which vaccine is best for you, talk to your doctor or other health care professional.
Are quadrivalent flu vaccines safe?
هل لقاح الأنفلونزا الرباعي آمن؟
بالتأكيد هو آمن مع الغالبية ولا يسبب الأنفلونزا لأن الفيروسات المستخدمه فيه ميته أو ضعيفة أو مصنعة بطريقة لا تتضمن فيروس الأنفلونزا
Yes. Flu vaccines that protect against four flu viruses have a safety profile similar to seasonal flu vaccines made to protect against three viruses, with similar—mostly mild—side effects. Like all seasonal flu vaccines, vaccines that protect against four flu viruses are monitored annually for their safety and effectiveness.
Quadrivalent vaccine cannot cause flu illness because they contain ‘inactivated’ (killed) virus, attenuated (weakened) virus, or are made using recombinant methods that don’t use flu virus in the manufacturing process.
Special Consideration Regarding Egg Allergy
من لديهم حساسية من البيض لابد أن يؤخذ ذلك في الأعتبار ويوجد أمصال تصلح لهم ولا تسبب آي حساسية
People with egg allergies can receive any licensed, recommended age-appropriate influenza vaccine (IIV4, RIV4, or LAIV4) that is otherwise appropriate. People who have a history of severe egg allergy (those who have had any symptom other than hives after exposure to egg) should be vaccinated in a medical setting, supervised by a health care provider who is able to recognize and manage severe allergic reactions. Two completely egg-free (ovalbumin-free) flu vaccine options are available: quadrivalent recombinant vaccine and quadrivalent cell-based vaccine.
https://www.cdc.gov/flu/prevent/quadrivalent.htm
https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm
عندما تقرأ تتعلم وتفهم وعندما تتعلم وتفهم يمكن أن تتكلم
When you read you learn and understand, and when you learn and understand YOU CAN TALK
Saturday, September 18, 2021
Friday, June 25, 2021
Booster shots هل سيحتاج الناس إلى جرعة ثالثة؟ الآن يبحثوا الجرعة الثالثة للعاملين بالمجال الطبي وكبار السن!
حيث أنهم لا يعلمو مدى تحصين اللقاح لإخذه والمدة التي ينتهي فيها التأثير ويعود الشخص عرضة للمرض مره أخرى أو يبدأ في أخذ جرعات من اللقاح جديدة! لتأمين دوام الوقاية تماماً مثل لقاحات الأنفلونزا هنا يتكلموا عن الجرعة الثالثة أو المنشطة !! كذلك سيتم الأعتراف قريباً بأن لقاحات فايزر وموديرنا تسبب في بعض الأشخاص أعراض قد تكون مميتة في عضلة القلب
Booster shots may NOT be needed this autumn but the elderly and NHS will be first in line if they are, claims one of No10's top vaccine advisers
Booster Covid vaccines may not be needed this autumn, one of the Government's top experts claimed today.
Professor Adam Finn, from the Joint Committee on Vaccination and Immunisation (JCVI) - which advises No10, insisted top-up jabs may well be required for the very elderly and NHS workers.
But he admitted there was still a 'high level of uncertainty' over whether they would be necessary for millions of other Brits.
Scientists had expected the protection given by vaccines to begin to wear off over time but they don't yet know how long immunity from Covid jabs lasts for.
Influenza vaccines are needed every winter because the virus is constantly evolving to beat the human immune system.
Coronaviruses tend to mutate slower and academics have claimed they've yet to see any proof of waning immunity in vaccinated Britons.
Last month Matt Hancock announced at a Downing St press conference scientists were beginning trials of a third jab to check if it offers better protection.
Millions more vaccine doses than necessary have been bought by the Government and a giant order of 60million more Pfizer doses in April was earmarked for a top-up campaign in the autumn.
==============================
British health chiefs could soon issue a warning that Pfizer and Moderna's Covid jabs are linked to heart issues in extremely rare cases, experts believe.
Fears about the two jabs causing myocarditis have grown in recent weeks, following a string of cases in young adults and children in Israel and the US.
American regulators have already accepted there is a 'likely link' between the heart condition and the vaccines, and will add warnings about the potential complication on information sheets given to the public.
Last week the Medicines and Healthcare products Regulatory Agency (MHRA), which polices the safety of drugs in the UK, said rates of myocarditis among vaccinated adults were 'similar or below' expected levels.
But last night, MailOnline can reveal the watchdog dropped all mention of how often the complication was occurring. Instead, it just updated its weekly summary to say cases were 'very rare' and 'typically mild'.
One cardiologist said he believed it the change in tone may signal that the body was going to accept a link between the two vaccines and myocarditis.
Other experts warned it further complicated the debate about vaccinating children in Britain.
============================================================
WHAT IS MYOCARDITIS?
Myocarditis is an inflammation of the heart muscle. There are no specific causes of the condition but it is usually triggered by a virus.
Some of the most common infections which cause myocarditis, are those called adenovirus and Coxsackie B.
It can be caused by the common cold, hepatitis B and C, and herpes simplex virus.
The most common symptoms of the condition include chest pain, a fever, a fast heartbeat, tiredness and shortness of breath.
If the inflammation damages the heart muscle or the fibres that conduct electrical pulses to the heart, complications can develop.
They can develop quickly, and include sudden loss of consciousness, an abnormally fast, slow or irregular heartbeat.
In very severe cases the condition is fatal, causing heart failure or sudden death. The inflammation enlarges the heart and creates scar tissue, forcing it to work harder and therefore making it weaker.
In most cases of viral myocarditis, the illness goes away and there are no complications.
But in rare cases when inflammation is severe, there can be damage to the heart which needs monitoring and possibly a heart transplant.
Myocarditis can reoccur, but there is no known way to prevent this. The risk of recurrence is low, around 10 to 15 per cent, according to Myocarditis Foundation.
It is difficult to gauge the prevalence of myocarditis because there is no widely available test for it.
In 2010, approximately 400,000 people died of heart muscle disease - cardiomyopathy that includes myocarditis - worldwide.
Expert consensus opinion estimates that up to 40 per cent of dilated cardiomyopathy results from myocarditis, according to the National Organisation for Rare Disorders.
الموضوع في دايلي ميل
https://www.dailymail.co.uk/news/article-9725051/UK-health-chiefs-say-rates-myocarditis-higher-expected-amoung-young-adults.html
Wednesday, June 23, 2021
AstraZeneca & Pfizer's jabs some problems (quoted from https://www.dailymail.co.uk/news/article-9712333/
Four British men develop potentially deadly Guillain-Barré syndrome just days after having AstraZeneca's Covid jab
- Four men in Nottingham developed Guillain-Barré syndrome after a Covid jab
- Cases linked to AstraZeneca's vaccine but scientists have not identified cause
- Six cases of the syndrome were also identified in Australia and seven in India
Four British men have developed a potentially life-threatening condition just days after having AstraZeneca's Covid vaccine.
The recipients developed Guillain-Barré syndrome, which can cause paralysis and leave patients in crippling pain.
All four cases were spotted in the Nottingham area, where around 700,000 people have had the British firm's coronavirus jab.
British health chiefs have yet to offer a public breakdown of how many cases of the syndrome have been spotted in vaccine recipients across the entire country.
But a similar link has been spotted in both Australia and India, where AstraZeneca's vaccine is also being dished out. It is also a known rare side effect of flu and HPV jabs.
AstraZeneca's jab — which is given as a double-dose — has also been heavily linked to deadly blood clots in younger adults.
For that reason, UK drug watchdogs have recommended under-40s, who face a tiny risk of falling seriously ill with Covid, get alternative jabs.
But data is now also emerging that shows Pfizer's jab — the other main option being administered in the UK — may cause heart inflammation.
Cases of Guillain-Barre syndrome after AstraZeneca's vaccine were described in two separate studies in the journal Annals of Neurology.
The complication — normally triggered by an infection — usually occurs in around one in 100,000 people in the UK and US.
What is Guillain-Barre syndrome?
Guillain–Barré syndrome is a rare disorder in which the immune system goes into overdrive and the body attack its own nerves.
Common symptoms of the rare condition include weakness and tingling in the limbs.
As patients' conditions worsen, this can lead to parts of the body — or in some cases the whole body — being paralysed.
The syndrome is rare, affecting about one in 100,000 annually in the UK and US.
Fewer than 20,000 cases are diagnosed per year in the US, according to the National Institute of Neurological Disorders and Stroke.
Doctors say it is often triggered by a viral or bacterial illness, such as Campylobacter jejuni.
There is no cure. Treatment focuses on restoring the nervous system.
It can be fatal if it involves the respiratory muscles.
But doctors in India who also uncovered the link say it was occurring up to 10 times more than expected.
One of the articles published in the journal broke down the cases spotted in Nottingham, which all occurred within ten days of each other.
Symptoms began 11 to 22 days after the first jab and all of the four men were aged between 20 and 57.
One had no relevant medical history. The three others others had ulcerative colitis, asthma and high blood pressure.
None had been infected with Covid. They were treated with antibodies and steroid pills.
Dr Christopher Allen, a clinical neuroscientist at Nottingham University, who wrote the article, admitted they cannot be certain the jab caused the neurological illness and it could have happened by chance.
But it demonstrates the need for 'robust post-vaccination surveillance,' he said. And he added vaccines currently deployed are 'very safe'.
Dr Allen added the reaction may be 'a cross-reactive immune response to the SARS-CoV-2 spike protein', causing the immune system to overreact and the body to attack its own nerves.
Dr Allen said if the condition is caused by AstraZeneca's vaccine, it will be because spike proteins contained in the firm's viral vector technology.
Pfizer's and Moderna's MRNA vaccines do not contain the same spike proteins, so are unlikely to see similar links to the syndrome.
The second paper by neurologists at the Aster Medcity hospital in Kochi, Kerala, identified seven cases of severe Guillain-Barré syndrome.
They were struck down within a fortnight of receiving the first AstraZeneca vaccine.
Lead author Dr Boby Varkey Maramattom said rates of the condition were between 1.4 and 10-fold higher than would normally be expected.
And the patients suffered 'unusually severe' facial weakness — one of the symptoms of the condition.
Four of the cases involved women aged 40 to 70 years — three of whom required mechanical ventilation.
Nerve damage around the face and head occurred in four patients — which happens in less than five per cent of Guillain-Barré syndrome cases.
Dr Maramattom said while the findings suggested the vaccine could be to blame a clear link had been proven and it is 'unlikely' the jabs had triggered the syndrome in all cases.
The benefits of vaccination also 'substantially outweigh the risk of this relatively rare outcome,' he said.
Covid itself is also linked to Guillain-Barré syndrome, with the virus believed to have triggered the condition in a man, 54, in New Jersey in April 2020.